MIMEDX GROUP, INC.
Close on Oct 19, 2026
- Market cap
- $647.35M
- P/E (TTM)
- 109.5
- Dividend yield
- –
About Mimedx
Surgical & Medical Instruments & Apparatus, SIC 3841
MIMEDX develops and manufactures regenerative biomaterial products, primarily human placental allografts, animal-derived xenografts, and advanced wound dressings. The company operates across wound care, surgical specialties, and burn treatment sectors. Its product portfolio includes human placental membrane allografts, bovine collagen matrices, autologous platelet-rich plasma gels, and peptide matrices intended to assist in healing chronic wounds, surgical recovery, and internal tissue reinforcement. Customers include clinicians, hospitals, private physician practices, wound care clinics, ambulatory surgery centers, nursing homes, and federal healthcare facilities such as the Department of Veterans Affairs.
The company conducts most of its commercial business in the United States and distributes products internationally, including in Japan. It processes donated human birth tissue from a nationwide network of partner hospitals at manufacturing facilities located in Marietta and Kennesaw, Georgia, while the provided text does not state its headquarters location. Through December 2025, the business has supplied several million allografts and maintains nearly three hundred issued and pending patents worldwide.
Summary of the business section of Mimedx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MIMEDX GROUP, INC.
- Headquarters
- Marietta, GA
- Address
- 1775 W Oak Commons Court, Ne 30062
- Phone
- (770) 651-9100
- Employees
- 808, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- MDXG
- Exchange
- Nasdaq
- IPO date
- Feb 12, 2008
- Shares outstanding
- 146M, Jul 23, 2026
- Public float
- $719.00M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1376339
- CUSIP
- 602496101
- ISIN
- US6024961012
- EIN
- 26-2792552
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rice Doug | Chief Financial Officer | 399,566 |
| Kimberly Maersk-Moller | Chief Commercial Officer | 309,630 |
| William Frank Hulse IV | General Counsel and CAO | 543,195 |
| Ricci S. Whitlow | Chief Operating Officer | 462,825 |
| Joseph H. Capper | Chief Executive Officer | 904,656 |
| James L. Bierman | Director | 263,684 |
| Tiffany Olson | Director | 108,510 |
| William A. Hawkins | Director | 255,431 |
| Todd Newton | Director | 463,684 |
| Dorothy E. Puhy | Director | 108,510 |
| M. Kathleen Behrens | Director | 212,771 |
| Cato T. Laurencin | Director | 181,923 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Joseph H.Capper | $7.18M | -$14.96M | $2.10M | $75 | – |
| FY2024 Joseph H.Capper | $1.39M | $5.12M | $2.77M | $106 | – |
| FY2024 K.Todd Newton | – | $487.29K | $2.77M | $106 | – |
| FY2023 Joseph Capper | $20.83M | $37.01M | $2.52M | $97 | – |
| FY2023 Joseph H.Capper | $20.76M | $36.93M | $2.52M | $97 | – |
| FY2023 K.Todd Newton | $295.29K | $487.29K | $2.52M | $97 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 808 full time employees.”
Corporate history
Events identified from SEC filings